Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 7/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7440029 | 0.83 | HSD11B1 (0.36) | HSD11B1FFAR1HTTPKMALDH1A1 | |
| SCHEMBL27602702 | 0.83 | LMNA (0.32) | LMNA | |
| SCHEMBL9008595 | 0.81 | — | — | |
| SCHEMBL27812551 | 0.80 | — | — | |
| SCHEMBL28646433 | 0.79 | SMN1; SMN2 (0.34) | PKMALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL27385170 | 0.79 | HSD11B1 (0.35) | HSD11B1FFAR1HTTPKMKMT2A | |
| SCHEMBL27602697 | 0.78 | HSD11B1 (0.33) | HSD11B1FFAR1 | |
| SCHEMBL8754613 | 0.77 | L3MBTL1 (0.30) | — | |
| SCHEMBL27589277 | 0.77 | HSD11B1 (0.33) | HSD11B1FFAR1HTTALDH1A1MAPT | |
| SCHEMBL3947332 | 0.76 | THRB (0.31) | TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103274961-B | The Compounds and methods for for the treatment of cell generation disorders | KINEX PHARMACEUTICALS LLC (US) | 2016-05-18 | — | — | CN | disclosed |
| US-20140371198-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2014-12-18 | — | — | US | disclosed |
| CN-103274961-A | Compositions and methods of treating cell proliferation disorders | KINEX PHARMACEUTICALS LLC | 2013-09-04 | — | — | CN | disclosed |
| CN-101184734-B | Compounds and methods for treating cell proliferation disorders | KINEX PHARMACEUTICALS LLC | 2013-05-29 | — | — | CN | disclosed |
| CN-101184734-A | Compounds and methods for treating cell proliferation disorders | KINEX PHARMACEUTICALS LLC (US) | 2008-05-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371198-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC AND INFLAMMATORY DISEASES | GOT2, GPR119, PC | HSD11B1 330/4885FFAR1 59/4885HTT 3823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.